APL-1030

APL-1030 is a recombinant 64–amino acid Nanofitin-based complement inhibitor that binds primate complement component C3 and its fragment C3b with low-nanomolar affinity, blocking both classical and alternative pathway activation of the complement cascade.[1][4] Developed by Apellis Pharmaceuticals in collaboration with Affilogic’s Nanofitin platform, APL-1030 is being positioned as a first-in-class, brain-active C3 inhibitor and as a secreted payload for gene therapy constructs to enable sustained, local modulation of complement activity in the central nervous system and other tissues for neurodegenerative and complement-driven diseases.[1][2][3][5][7][8] The molecule’s small, thermostable protein scaffold and all–natural amino acid composition are designed to support recombinant production, tissue-targeted and bifunctional constructs, and gene therapy–based delivery strategies in indications such as neurodegenerative disorders and age-related macular degeneration.[1][2][3][7][8]

Other names

APL-1030 nanofitin C3 inhibitorAPL1030 nanofitin C3 inhibitorAPL 1030 nanofitin C3 inhibitorAPL 1030 gene therapyAPL1030 gene therapyAPL-1030 gene therapy